A New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral Protein Expression in the Development of Lymphomas
Open Access
- 1 January 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (1), 165-177
- https://doi.org/10.1128/jvi.01512-10
Abstract
Epstein-Barr virus (EBV) infects cells in latent or lytic forms, but the role of lytic infection in EBV-induced lymphomas is unclear. Here, we have used a new humanized mouse model, in which both human fetal CD34 + hematopoietic stem cells and thymus/liver tissue are transplanted, to compare EBV pathogenesis and lymphoma formation following infection with a lytic replication-defective BZLF1-deleted (Z-KO) virus or a lytically active BZLF1 + control. Both the control and Z-KO viruses established long-term viral latency in all infected animals. The infection appeared well controlled in some animals, but others eventually developed CD20 + diffuse large B cell lymphomas (DLBCL). Animals infected with the control virus developed tumors more frequently than Z-KO virus-infected animals. Specific immune responses against EBV-infected B cells were generated in mice infected with either the control virus or the Z-KO virus. In both cases, forms of viral latency (type I and type IIB) were observed that are less immunogenic than the highly transforming form (type III) commonly found in tumors of immunocompromised hosts, suggesting that immune pressure contributed to the outcome of the infection. These results point to an important role for lytic EBV infection in the development of B cell lymphomas in the context of an active host immune response.Keywords
This publication has 41 references indexed in Scilit:
- Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rγnull miceHuman Immunology, 2010
- AP-1 homolog BZLF1 of Epstein–Barr virus has two essential functions dependent on the epigenetic state of the viral genomeProceedings of the National Academy of Sciences of the United States of America, 2009
- Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy VolunteersJournal of Virology, 2009
- Priming of protective T cell responses against virus-induced tumors in mice with human immune system componentsThe Journal of Experimental Medicine, 2009
- CD34+ Cord Blood Cell-Transplanted Rag2−/− γc−/− Mice as a Model for Epstein-Barr Virus InfectionThe American Journal of Pathology, 2008
- Epstein-Barr Virus Lytic Transactivator Zta Enhances Chemotactic Activity through Induction of Interleukin-8 in Nasopharyngeal Carcinoma CellsJournal of Virology, 2008
- Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomasLeukemia & Lymphoma, 2008
- EBV the prototypical human tumor virus—just how bad is it?Journal of Allergy and Clinical Immunology, 2005
- Persistence of the Epstein–Barr Virus and the Origins of Associated LymphomasNew England Journal of Medicine, 2004
- Epstein–Barr Virus-Induced B-Cell Lymphoma after Renal TransplantationNew England Journal of Medicine, 1982